PLK1 and neoplasm: Several small molecule inhibitors of PLK1 are being evaluated in clinical trials and we selected four of these compounds to test on tumor (VU-SCC-120 and UM-SCC-22A) and preneoplastic (VU-preSCC-M3) cell lines, as well as on primary keratinocytes.